Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 4:8:551889.
doi: 10.3389/fpubh.2020.551889. eCollection 2020.

Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials

Affiliations
Review

Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials

Ramin Rahmanzade et al. Front Public Health. .

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is challenging the health care systems around the world and compelling them to timely share their strategies, tactics and experiences. Since mid-January, a huge volume of instructions has been released by Iran's Ministry of Health and Medical Education (MOHME) covering diverse aspects of disease control and prevention. In this study, we aimed to review the instructions published either before or after COVID-19's transmission to Iran to depict the clinical approach and therapeutics used in Iran to battle the current pandemic. We retrospectively gathered and critically reviewed all official situation reports, guidelines, guidance, flowcharts, protocols, recommendations and advice released by Iranian scientific, or administrative arms of action against COVID-19. The ongoing clinical trials approved by MOHME and registered to the Iranian Registry of Clinical Trials (IRCT) have been reviewed as well. Our study resulted in the following mainstays of Iran's approach to COVID-19: (i) active clinical screening; preferably on-line or on-phone, (ii) management of limited paraclinical resources; by using them as diagnostic tools rather than epidemiological, (iii) a trend toward outpatient care of mild-to-moderate cases; either confirmed or suspicious, with active scheduled follow-up, and (iv) avoidance of pharmacotherapy, as far as possible. The therapeutic and administrative instructions are still being actively updated with some recommendations different from the previous ones. Nevertheless, a common approach in the background could be detected, It seems that the instructions are conceptually in line with the first "National Guideline for 2019-nCoV" published on 20 January 2020. The screening has mainly been clinically oriented rather than being based on laboratory tests and MOHME seems to be following the approach of "early detection of symptomatic cases followed by early source control."

Keywords: COVID-19; Iran; SARS-CoV-2; antiviral therapy; infection prevention and control; public health.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Iran's Flowchart of Clinical Approach to COVID-19 (10).

Similar articles

Cited by

References

    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. (2020) 323:1239–42. 10.1001/jama.2020.2648 - DOI - PubMed
    1. WHO Timeline-COVID-19. Available online at: https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19.
    1. Iran's National Guideline for 2019-nCoV; 1st edition Available online at: https://firoozgar.iums.ac.ir/files/baharestan/files/dam.pdf.
    1. Iran's National Guideline for 2019-nCoV; 2nd edition Available online at: https://firoozgar.iums.ac.ir/files/baharestan/files/kesh.pdf.
    1. WHO's Situation Report-30 Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....